Frontiers | Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
Daratumumab Forms Backbone of Triplet Regimens in Transplant Ineligible Multiple Myeloma
Treatment Options for Newly Diagnosed MM - Expert Guidance: Myeloma - Module - Myeloma Therapeutic Strategies - Oncology - Clinical Care Options
Federal Practitioner - 0918 Current Trends in MM - Current Trends in Multiple Myeloma
Short overview on the current standard of treatment in newly diagnosed multiple myeloma | SpringerLink
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Frailty Assessment. Abbreviations: IMWG, International Myeloma Working... | Download Scientific Diagram
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Updated Perspectives on the Management of Multiple Myeloma in Older Pa | CIA
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
PDF) Cooccurrence of classic Hodgkin lymphoma and multiple myeloma
Management of Transplant-Ineligible Multiple Myeloma
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Cancers | Free Full-Text | Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond | HTML
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies | HTML
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, E | CMAR
Multiple myeloma - The Lancet
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022 in: Journal of the National Comprehensive Cancer Network Volume 20 Issue 1 (2022)
Lipe Discusses Therapeutic Options for a Patient With Transplant-Ineligible Multiple Myeloma
